Two more vaccine candidates are cleared to join the Tumaini Ebola trial in the Democratic Republic of the Congo

5 November 2026

The World Health Organization says two further vaccine candidates will be added to Tumaini, the multi-vaccine study running against Ebola in the Democratic Republic of the Congo.
One is ChAdOx1, built by the University of Oxford together with the Serum Institute of India; the other is Moderna's mRNA-1469.
WHO's independent Technical Advisory Group on Candidate Vaccines Prioritization picked out both for further clinical evaluation, and each will join once the country's own regulators clear it.
Tumaini, a Swahili word for hope, began on 23 October at Bunia, the provincial capital of Ituri in the east.
It puts several candidates through one study and relies on ring vaccination, in which the people around a confirmed case are immunised.
Four such rings have been set up.
The epidemic behind it is of the Bundibugyo species and is the country's largest, standing at more than 10,500 confirmed cases and 5,126 deaths on 1 November.